Patents
Literature
Patsnap Eureka AI that helps you search prior art, draft patents, and assess FTO risks, powered by patent and scientific literature data.

173 results about "Circulating DNA" patented technology

Circulating tumor DNA (ctDNA) is tumor-derived fragmented DNA in the bloodstream that is not associated with cells. ctDNA should not be confused with cell-free DNA (cfDNA), a broader term which describes DNA that is freely circulating in the bloodstream, but is not necessarily of tumor origin.

Methods and systems for generating sequencing libraries

Methods and systems for targeted detection of circulating tumor DNA (ctDNA) molecules are disclosed herein. In some cases, a molecular sequencing library depleted of methylated DNA can be generated and used to detect ctDNA in a cell-free DNA sample reliably at a lower sequencing depth and lower cost than existing methods.
Owner:ADELA INC

Methods for assaying circulating tumor DNA

The present disclosure includes a method of comprising (a) obtaining cell-free DNA (cfDNA) from a sample from a subject; (b) selectively enriching subsets of the cfDNA from (a) or derivatives therefrom having one or more target regions to obtain enriched DNA, wherein the target regions are differentially methylated in cancer; (c) sequencing the enriched DNA from (b) to obtain sequence reads; and (d) partitioning a plurality of the sequence reads into two or more groups based on their methylation status and determining the fragment length distribution of the sequence reads in at least one of the groups.
Owner:NATERA INC

Ultra-high depth sequencing-based tiny residual focus detection method and system

The invention discloses a tiny residual focus detection method and system based on ultra-high depth sequencing, and relates to the technical field of tiny residual focus intelligent detection.The tiny residual focus detection method comprises the following steps that on the basis of a sequencing library, splitting is conducted according to a sample index to obtain a to-be-detected sample, and a consensus sequence is obtained according to a molecular identifier of the to-be-detected sample; based on a consensus sequence, filtering out the consensus sequence of which the mass value is less than 25 or the family size is less than 3, and combining a variation type and a distance from a fragment edge as noise introduced into an original nucleic acid molecular chain; a context sequence (context) and a chain direction are used as noise for introducing the capture level of PCR amplification; on the basis of the noise level, the circulating tumor DNA level is estimated in combination with tumor priori knowledge, and the MRD state is determined by detecting the significance of molecular signal sources. According to the invention, the sensitivity and specificity of MRD detection are improved.
Owner:GENECAST (BEIJING) BIOTECHNOLOGY CO LTD +1

Methods of detecting and enriching circulating tumor DNA

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.
Owner:MYRIAD WOMENS HEALTH INC

Circulating tumor DNA biosensor and construction method and application thereof

The invention discloses a circulating tumor DNA biosensor and a construction method and application thereof, and belongs to the technical field of biosensors. The dual-mode ratio type circulating tumor DNA biosensor comprises a sensing substrate assembled with a triangular DNA probe, a probe solution and exonuclease. The triangular DNA probe is used as an anchoring substrate to support target cycle amplification, and the sensitivity of the biosensor is effectively improved by using an ECL-RET effect and an enzyme-assisted target cycle signal amplification strategy; and the FL / ECL ratio is used as a dual-mode signal output strategy, so that the accuracy and feasibility of the detection technology are improved. The biosensor is high in accuracy, high in sensitivity and good in selectivity, quantitative detection of PIK3CA E545K ctDNA in blood of a breast cancer patient can be achieved, and the biosensor has important application value in the fields of clinical diagnosis and drug research of breast cancer.
Owner:XUZHOU CENT HOSPITAL

Methods of preparing a DNA fraction enriched with circulating tumor DNA

The present disclosure relates to a laboratory execution system that provides for automation of laboratory processes. A centralized data management system may be dynamically updated and used to facilitate management of components of the laboratory execution system, such as an automation system and an analytics results management system that may facilitate complex analytical functions, such as synthesizing raw test data. Potential workflows include the detection of specific molecules of interest.
Owner:MYRIAD WOMENS HEALTH INC

Method for constructing plasma ctDNA organ distribution characteristic chromatogram of advanced colorectal cancer

PendingCN121687190AMicrobiological testing/measurementBiostatisticsDeoxyriboseClinicopathologic feature
The invention relates to the technical field of biomedicine, in particular to a method for constructing a plasma ctDNA organ distribution characteristic spectrum of advanced colorectal cancer. The method comprises the following steps: collecting a peripheral blood sample at multiple time points, separating plasma by adopting a double-centrifugal method, and extracting circulating tumor DNA (Deoxyribose Nucleic Acid); carrying out whole exome sequencing based on ctDNA to obtain genome variation information and calculating variation allele frequency, and synchronously detecting the expression quantity of immune-related proteins by adopting an Olink proteomics technology; integrating the genome data, the protein expression data and the clinical pathological features, and constructing a multi-dimensional feature data matrix; and taking the organ metastasis condition confirmed by iconography as a supervision label, training a model by applying a machine learning algorithm, screening key prediction factors, constructing a quantitative prediction model, and finally generating a visual organ metastasis tendency prediction map. According to the method, early and accurate prediction of the advanced colorectal cancer organ metastasis tendency is realized through multi-omics data collaborative analysis and machine learning modeling.
Owner:CHINESE PEOPLES ARMED POLICE FORCE CHARACTERISTIC MEDICAL CENT

Dynamic minimal residual disease detection

PCT designated stage expiredWO2025024829A1BiostatisticsProteomicsMRD NegativeDisease
The present disclosure relates to systems and methods for detecting circulating tumor DNA (ctDNA) and minimal residual disease in a patient sample..Aspects of the present disclosure relate to use of a classification module to assess whether a patient sample comprises ctDNA and minimal residual disease based, in part, on patient-specific inputs. The present disclosure is also related, at least in part, to a determination of whether a patient has cancer based on an output of the classification module.
Owner:THE BROAD INST INC

Predicting response to neoadjuvant treatment in non-small cell lung cancer

The disclosure relates to methods of assessing the success of treatment with durvalumab and chemotherapy for resectable non-small cell lung cancer (R-NSCLC) in patients based on circulating tumor DNA (ctDNA) detection, ctDNA clearance and / or partial clearance and / or variant allele fraction (VAF) before and after such treatment. The disclosure also relates to methods for treating patients with R-NSCLC based on ctDNA detection, ctDNA clearance and / or partial molecular clearance and / or VAF before and after such treatment.
Owner:ASTRAZENECA AB

Micro residual focus monitoring method and system based on circulating tumor DNA

The invention discloses a high-specificity minimal residual disease (MRD) monitoring method and system based on circulating tumor DNA (ctDNA). The method comprises the following steps: receiving tumor tissue sequencing data of an UTUC patient, and generating a double-Panel target list containing personalized and fixed Panel; respectively extracting plasma cfDNA and leukocyte gDNA; performing vacuum concentration, hybrid capture and sequencing on the cfDNA library by using the double Panel lists, and performing deep sequencing on the leukocyte gDNA; constructing an individualized clonal hematopoietic mutation filtering database; actively filtering and rejecting clonal hematopoietic background mutation by utilizing a filtering database; and calculating an MRD load score based on the filtered tumor-derived mutation and outputting a report. The system comprises corresponding modules which are used for automatically executing the process. According to the invention, through cooperation of four major technologies of double-Panel design, process optimization, UMI error correction and active clonal hematopoietic filtration, MRD monitoring with extremely high sensitivity and specificity on UTUC is realized, false positive is significantly reduced, and the kit has drug resistance early warning potential.
Owner:MAIYUE BIOTECHNOLOGY (SUZHOU) CO LTD

Monitoring circulating tumor DNA (CTDNA)

Provided herein are methods for monitoring, identifying, assessing, circulating tumor DNA (ctDNA) for treating a subject or monitoring a subject having cancer, and related methods and uses thereof. In some embodiments, the disease or condition is a B cell lymphoma (BCL) relapsed or refractory.
Owner:FORESIGHT DIAGNOSTICS INC +1

Circulating tumor DNA (deoxyribonucleic acid) standard substance as well as preparation method and valuing method thereof

The invention discloses a circulating tumor DNA (deoxyribonucleic acid) standard substance as well as a preparation method and a valuing method thereof. The preparation method comprises the following steps: (1) culturing cells; (2) cell nucleus extraction; (3) carrying out enzyme digestion on cell nucleuses; (4) purifying the fragmented DNA; (5) sampling a sample, and quantifying the sample by nanodrop measurement; (6) sampling the length of a verification fragment; and (7) mixing different ctDNAs according to the finally obtained theoretical mutation abundance of 1%, 5% and 10% to prepare the standard substance. The valuing method comprises the following steps: carrying out digital PCR amplification on a sample through a double-labeled probe to obtain the copy number concentration of a mutant gene and a wild gene or the copy number concentration of a target gene and a reference gene, and calculating the gene mutation frequency and the amplification multiple. According to the method disclosed by the invention, the fragmented DNA with the length similar to that of the ctDNA is obtained; 330bp and large fragments can be removed through two rounds of purification of a paramagnetic particle method, and a single-fragment standard substance is obtained.
Owner:NATIONAL INSTITUTE OF METROLOGY CHINA

Use of multi-nucleotide and structural variants for improved sensitivity and specificity of circulating tumor DNA assays

Described herein are methods of preparing an enriched library of nucleic acids, comprising: (a) identifying a patient-specific panel of somatic variants present in a tumor sample from a patient, (b) generating a subset panel of somatic variants from the patient-specific panel, wherein the subset of somatic variants comprises one or more of: multi -nucleotide variants, insertions and deletions, and genomic rearrangements; (c) preparing a sample of cell-free DNA (cfDNA) fragments from the patient for sequencing; and (d) selectively enriching the cfDNA for the subset of somatic variants to generate an enriched library.
Owner:MYRIAD WOMENS HEALTH INC

Drug-resistant gene mutation EGFR T790M / C797S cis-trans typing method

The invention relates to the technical field of biology, in particular to a cis-trans typing method for drug-resistant gene mutation EGFR T790M / C797S. The invention provides an EGFR (Epidermal Growth Factor Receptor) T790M / C797S cis-trans typing method based on a locked nucleic acid LNA (Low Nucleic Acid) probe, ultrahigh-specificity DNA (Deoxyribose Nucleic Acid) polymerase and a primer probe combination. The typing method can be used for accurately distinguishing EGFR T790M / C797S double-mutation cis-configuration and trans-configuration; meanwhile, the kit has the advantages of high sensitivity, high specificity, simple steps and low cost, is suitable for detecting low-abundance samples such as circulating tumor DNA (ctDNA) and can meet the clinical rapid detection requirement.
Owner:THE FIRST AFFILIATED HOSPITAL OF SOOCHOW UNIV

Tumor fraction and outcome association in a real-world non-small cell lung cancer (NSCLC) cohort using a methylation-based circulating tumor DNA (CTDNA) assay

PCT designated stage expiredWO2025106837A1BiostatisticsProteomicsAssayCirculating tumor DNA
Provided herein are methods of determining a molecular response score for use in predictive models, including scoring based on epigenetic methylation based detection of mutant allele fraction. The molecular response score may be used to monitor and guide administration of treatment to a subject.
Owner:GUARDANT HEALTH INC

Method and system for predicting early gastric cancer prognosis by circulating marker

The invention provides a method and a system for predicting early gastric cancer prognosis by a circulating marker, and relates to the technical field of auxiliary diagnosis. The method comprises the following steps: performing multi-omics detection on a blood sample based on a preset sampling time sequence to obtain a multi-dimensional time sequence characteristic data set containing three groups of heterogeneous data of circulating tumor DNA, exosomes and protein markers; calculating a change slope and a fluctuation variance of the heterogeneous data in adjacent time sequence intervals, constructing a dynamic variation feature matrix in combination with a standard attenuation weighting factor, and deeply mining spatial cross-correlation and sequence dependence features of the matrix to generate a multi-modal fusion feature fingerprint; and performing regression operation on the feature fingerprints by using an integrated learning stack model to obtain a dynamic prognosis risk score, and further retrieving a risk hierarchical mapping table to generate a prognosis evaluation result containing a survival curve. According to the method, multi-modal heterogeneous data can be effectively fused, the biological dynamic characteristics in the tumor postoperative recovery phase are captured, and the accuracy and timeliness of early gastric cancer prognosis prediction are remarkably improved.
Owner:THE FIRST MEDICAL CENT CHINESE PLA GENERAL HOSPITAL

Application of circulating tumor cells and circulating tumor DNA (Deoxyribose Nucleic Acid) of peritoneal lavage fluid to prediction of allogenic peritoneal metastasis after radical gastric cancer operation

ActiveCN118979107ATimely and effective formulationformulate effectiveMicrobiological testing/measurementDrug and medicationsOncologyAdvanced gastric cancer
The invention relates to the technical field of biology, in particular to detection of circulating tumor cells and circulating tumor DNA (deoxyribonucleic acid) based on abdominal cavity lavage fluid and application of the detection in predicting the risk of allogenic peritoneal metastasis after a radical gastric cancer operation. How to recognize micro-metastasis in the abdominal cavity and delay the occurrence and development of the micro-metastasis in a patient with gastric cancer in the progression stage becomes a problem urgently needing to be solved in the field of gastric surgery at present. The invention provides an application of detecting circulating tumor cells and circulating tumor DNA (ctDNA) in abdominal cavity lavage fluid to predict the risk of allogenic peritoneal metastasis after a radical gastric cancer operation. The latent peritoneal metastasis can be screened, judged and follow-up visited in multiple stages, more comprehensive and sensitive information is provided, and clinical decision making and treatment scheme making can be guided.
Owner:RENJI HOSPITAL AFFILIATED TO SHANGHAI JIAO TONG UNIV SCHOOL OF MEDICINE

Circulating tumor DNA fraction and uses thereof

Disclosed herein are methods of treating an individual having cancer, of treating or identifying an individual having cancer for a treatment, or stratifying individuals having cancer for a treatment based on a tumor shed value determination in a liquid biopsy sample. Also described herein are methods of analyzing a biomarker based on a tumor shed value determination in a liquid biopsy sample.
Owner:FOUNDATION MEDICINE INC

Genomic alterations in the tumor and circulation of pancreatic cancer patients

Pancreatic adenocarcinoma has the worst overall mortality of any solid tumor, with only 7% of patients surviving after 5 years. To evaluate the clinical implications of genomic alterations in this low cellularity tumor type, we deeply sequenced the genomes of 101 enriched pancreatic adenocarcinomas from patients who underwent potentially curative resections and used non-invasive approaches to examine tumor specific mutations in the circulation of these patients. These analyses revealed somatic mutations in chromatin regulating genes including MLL and ARID1A in 20% of patients that were associated with improved survival. Liquid biopsy analyses of cell free plasma DNA revealed that 43% of patients with localized disease had detectable circulating tumor DNA (ctDNA) in their blood at the time of diagnosis. Detection of ctDNA after resection predicted clinical relapse and poor outcome, and disease recurrence by ctDNA was detected 6.5 months earlier than with standard CT imaging.
Owner:JOHNS HOPKINS UNIVERSITY

Monitoring circulating tumor DNA (ctDNA)

PendingCN122663294ADiseaseCirculating tumor DNA
Provided herein are methods for monitoring, identifying, evaluating circulating tumor DNA (ctDNA) for treating a subject or monitoring a subject having cancer, and related methods and uses thereof. In some embodiments, the disease or disorder is relapsed or refractory B-cell lymphoma (BCL).
Owner:FULL SAIL DIAGNOSTICS +1

Tumor identification and classification using fragmentomic features

Techniques for classifying cancers using fragmentomic features are described. An example method includes identifying data indicative of circulating tumor DNA (ctDNA) from a sample derived from a subject. The example method further includes identifying fragmentomic features based on the data. Input data, including the fragmentomic features, is input into a model configured to generate at least one probability that a tumor is within at least one category. The example method further includes generating a report based on the at least one probability that the tumor is within the at least one category.
Owner:FOUNDATION MEDICINE INC

Tumor identification and classification using fragmentomic features

Techniques for classifying cancers using fragmentomic features are described. An example method includes identifying data indicative of circulating tumor DNA (ctDNA) from a sample derived from a subject. The example method further includes identifying fragmentomic features based on the data. Input data, including the fragmentomic features, is input into a model configured to generate at least one probability that a tumor is within at least one category. The example method further includes generating a report based on the at least one probability that the tumor is within the at least one category.
Owner:FOUNDATION MEDICINE INC

Methods for detection and quantitation of circulating tumor DNA

Provided herein is a method of detecting circulating tumor DNA (ctDNA) in a sample. The method utilizes a preliminary panel that is cross-referenced with a second non-tumor sample to detect the presence or absence of any of the plurality of preliminary tumor-specific somatic mutations and removing said plurality of preliminary tumor-specific somatic mutations to obtain a patient-specific panel that can be used to detect ctDNA in further samples.
Owner:MYRIAD WOMENS HEALTH INC

Personalized tumor biomarkers

PendingUS20260002218A1Microbiological testing/measurementBlood plasmaRecurrent Tumor
Clinical management of human cancer is dependent on the accurate monitoring of residual and recurrent tumors. We have developed a method, called personalized analysis of rearranged ends (PARE), which can identify translocations in solid tumors. Analysis of four colorectal and two breast cancers revealed an average of nine rearranged sequences (range 4 to 15) per tumor. Polymerase chain reaction with primers spanning the breakpoints were able to detect mutant DNA molecules present at levels lower than 0.001% and readily identified mutated circulating DNA in patient plasma samples. This approach provides an exquisitely sensitive and broadly applicable approach for the development of personalized biomarkers to enhance the clinical management of cancer patients.
Owner:JOHNS HOPKINS UNIVERSITY

A preoperative risk assessment prediction method for liver transplantation patients with liver cancer

PendingCN122135790AMedical data miningHealth-index calculationGenomic sequencingLiver transplant recipient
This invention relates to the field of medical technology, specifically to a method for preoperative risk assessment and prediction in liver transplant patients with hepatocellular carcinoma, comprising the following steps: Sample collection: selecting plasma samples and corresponding clinicopathological information from liver transplant recipients of hepatocellular carcinoma, and clarifying the inclusion and exclusion criteria for samples; Plasma cell-free DNA extraction and whole-genome sequencing: extracting and quality-controlling cell-free DNA from the plasma samples collected in step S1, constructing a sequencing library, and performing low-coverage whole-genome sequencing. This invention utilizes plasma-extracted cfDNA for whole-genome sequencing, combined with clinical testing information, to construct a preoperative risk assessment and prediction model for postoperative recurrence in liver transplant recipients of hepatocellular carcinoma based on non-invasive testing. This model can be used to predict the probability of recurrence-free survival before liver transplantation. The model derivation cohort integrates clinical records and circulating tumor DNA data for preoperative recurrence risk prediction.
Owner:ZHEJIANG PROVINCIAL PEOPLES HOSPITAL

Methods for cancer detection and monitoring by means of personalized detection of circulating tumor DNA

The invention provides methods for detecting single nucleotide variants in breast cancer, bladder cancer, or colorectal cancer. Additional methods and compositions, such as reaction mixtures and solid supports comprising clonal populations of nucleic acids, are provided. For example, provided here is a method for monitoring and detection of early relapse or metastasis of breast cancer, bladder cancer, or colorectal cancer, comprising generating a set of amplicons by performing a multiplex amplification reaction on nucleic acids isolated from a sample of blood or urine or a fraction thereof from a patient who has been treated for a breast cancer, bladder cancer, or colorectal cancer, wherein each amplicon of the set of amplicons spans at least one single nucleotide variant locus of a set of patient-specific single nucleotide variant loci associated with the breast cancer, bladder cancer, or colorectal cancer; and determining the sequence of at least a segment of each amplicon of the set of amplicons that comprises a patient-specific single nucleotide variant locus, wherein detection of one or more patient-specific single nucleotide variants is indicative of early relapse or metastasis of breast cancer, bladder cancer, or colorectal cancer.
Owner:NATERA INC

Method for combined analysis of circulating dna methylation and fragmentomics based on targeted-cpg bisulfite sequencing

InactiveCN122629188ADiseaseEpigenetic Profile
The application discloses a free DNA methylation and fragmentomics combined analysis method based on targeted CpG bisulfite sequencing, and belongs to the technical field of liquid biopsy and epigenetic detection. The application extracts cfDNA from blood plasma, carries out high-throughput sequencing after library construction by a methylation adapter, bisulfite conversion, and biotin probe targeted capture of a CpG enrichment region, and simultaneously realizes single-base resolution methylation accurate quantification and FRAGMA fragmentomics analysis by using the same sequencing data, so that the accuracy of methylation quantification results is inferred, and the optimal detection region is iteratively selected; multi-dimensional characteristics such as a methylation ratio, an 11nt cutting map, a CGN / NCG motif ratio and a fragment length distribution are fused to construct a machine learning / deep learning model to output a unified disease risk score. The application realizes the bimodal integration of methylation chemical signals and fragmentomics structural signals in a targeted sequencing system for the first time, and has the advantages of low cost, high sensitivity and strong clinical adaptability.
Owner:MINGCHA HEALTH (SHENZHEN) TECHNOLOGY CO LTD